title: The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.
abstract: BACKGROUND
  This article describes the personal, societal, and economic burden attributable to schizophrenia in the People's Republic of China and highlights the potential for effective outpatient treatment to reduce this burden given recent changes in the Chinese health care system. The importance of effective antipsychotic therapy in reducing the burden of schizophrenia is also examined.
  
  
  METHODS
  Published research on the burden, disability, management, and economic costs of schizophrenia in the People's Republic of China was examined in the context of the larger body of global research. Research written in English or Chinese and published before June 2012 was identified using PubMed, CNKI, and Wanfang Med database searches. The contribution of effective antipsychotic therapy in reducing the risk for relapse and hospitalization and improving patients' functioning is described.
  
  
  RESULTS
  Schizophrenia imposes a substantial burden on Chinese society, with indirect costs accounting for the majority of the total cost. Functional impairment is high, leading to lost wages and work impairment. In the People's Republic of China, schizophrenia is the most common diagnosis among hospitalized psychiatric patients. Ongoing changes in the Chinese health care system may reduce some barriers to effective relapse prevention in schizophrenia and potentially reduce hospitalizations. The use of antipsychotics for acute episodes and maintenance treatment has been shown to decrease symptom severity and reduce the risk for relapse and hospitalization. However, discontinuing antipsychotic medication appears common and is a strong predictor of relapse. Cost-effectiveness research in the People's Republic of China is needed to examine the potential gains from improved outpatient antipsychotic treatment.
  
  
  CONCLUSIONS
  Schizophrenia is a very costly mental illness in terms of personal, economic, and societal burden, both in the People's Republic of China and globally. When treated effectively, patients tend to persist longer with antipsychotic treatment, have fewer costly relapses, and have improved functioning. Further research examining the long-term effects of reducing barriers to effective treatments on the societal burden of schizophrenia in the People's Republic of China is needed.
authors: Eli Lilly and Company, Sydney, NSW, Australia.
authors: William
authors: W
authors: Montgomery
authors: Li
authors: L
authors: Liu
authors: Michael D
authors: MD
authors: Stensland
authors: Hai Bo
authors: HB
authors: Xue
authors: Tamas
authors: T
authors: Treuer
authors: Haya
authors: H
authors: Ascher-Svanum
keywords: People’s Republic of China; antipsychotic agents; health care costs; relapse; review; schizophrenia
references: Singapore Med J. 2007 Nov;48(11):977-85
references: 17975685
references: Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626
references: 21249678
references: Schizophr Bull. 2003;29(1):15-31
references: 12908658
references: Psychiatr Serv. 2012 Jul;63(7):666-71
references: 22588167
references: Science. 2013 Feb 1;339(6119):505-7
references: 23371991
references: Schizophr Bull. 2008 Mar;34(2):229-44
references: 17905787
references: Schizophr Res. 2002 Apr 1;54(3):223-30
references: 11950547
references: Schizophr Bull. 2004;30(2):279-93
references: 15279046
references: Soc Psychiatry Psychiatr Epidemiol. 2011 Dec;46(12):1325-30
references: 21046070
references: N Engl J Med. 2005 Sep 22;353(12):1209-23
references: 16172203
references: Int J Clin Pharmacol Ther. 2010 Apr;48(4):270-4
references: 20353748
references: Psychol Med. 2009 Oct;39(10):1591-602
references: 19335931
references: N Engl J Med. 2005 Sep 15;353(11):1165-70
references: 16162889
references: J Psychiatr Res. 2012 Jul;46(7):856-64
references: 22575332
references: Psychiatr Serv. 2009 Jan;60(1):113-6
references: 19114581
references: Psychiatr Serv. 2004 Aug;55(8):886-91
references: 15292538
references: Aust N Z J Psychiatry. 2007 May;41(5):442-9
references: 17464737
references: Ann Gen Hosp Psychiatry. 2004 Jun 2;3(1):11
references: 15175112
references: BMJ. 2006 Jul 29;333(7561):224
references: 16825203
references: Qual Life Res. 2006 Nov;15(9):1459-69
references: 16957873
references: Schizophr Bull. 1995;21(3):419-29
references: 7481573
references: Schizophr Res. 2009 Mar;108(1-3):214-22
references: 19168329
references: Dialogues Clin Neurosci. 2001 Jun;3(2):109-19
references: 22033637
references: Arch Gen Psychiatry. 2010 Sep;67(9):895-904
references: 20819983
references: Schizophr Res. 2010 Nov;123(2-3):225-33
references: 20692814
references: Cochrane Database Syst Rev. 2012 May 16;(5):CD008016
references: 22592725
references: Lancet. 2009 Jan 3;373(9657):31-41
references: 19058842
references: J Clin Psychiatry. 2005 Jul;66(7):831-8
references: 16013897
references: Am J Psychiatry. 2009 Feb;166(2):152-63
references: 19015230
references: Br J Psychiatry. 2002 Dec;181:488-93
references: 12456518
references: Int J Methods Psychiatr Res. 2008;17(1):55-61
references: 18286464
references: Clin Ther. 2005 Feb;27(2):263-72
references: 15811492
references: J Clin Psychiatry. 2007 Jan;68(1):29-36
references: 17284127
references: Qual Life Res. 2010 Apr;19(3):317-22
references: 20135234
references: Am J Psychiatry. 2011 Jun;168(6):603-9
references: 21362741
references: Pharmacoeconomics. 2008;26(2):149-62
references: 18198934
references: CNS Drugs. 2012 Jun 1;26(6):491-508
references: 22668246
references: World Psychiatry. 2011 Oct;10(3):210-6
references: 21991281
references: J Clin Psychiatry. 2008 Jan;69(1):47-53
references: 18312037
references: Pharmacopsychiatry. 2009 Mar;42(2):66-71
references: 19308881
references: Am J Psychiatry. 1997 Sep;154(9):1228-34
references: 9286181
references: Shanghai Arch Psychiatry. 2012 Dec;24(6):305-21
references: 25324635
references: Arch Gen Psychiatry. 1999 Mar;56(3):241-7
references: 10078501
references: Neuropsychiatr Dis Treat. 2014 Jul 10;10:1287-96
references: 25031537
references: Psychiatry Clin Neurosci. 2004 Feb;58(1):61-7
references: 14678459
references: Eur Neuropsychopharmacol. 2013 Feb;23(2):118-25
references: 22633617
references: Eur Neuropsychopharmacol. 2005 Aug;15(4):399-409
references: 15925493
references: Lancet. 2009 Jun 13;373(9680):2041-53
references: 19524780
references: Psychiatr Serv. 2001 Jun;52(6):805-11
references: 11376229
references: Br J Psychiatry. 2004 Jun;184:509-16
references: 15172945
references: Dialogues Clin Neurosci. 2010;12(3):393-407
references: 20954433
references: Acta Psychiatr Scand. 2005 Mar;111(3):220-31
references: 15701107
references: J Clin Psychiatry. 2012 Jun;73(6):837-42
references: 22480452
references: Psychiatry Res. 2008 Apr 15;158(3):306-15
references: 18243334
references: J Clin Psychopharmacol. 2008 Jun;28(3):271-8
references: 18480683
references: J Korean Med Sci. 2008 Apr;23(2):167-75
references: 18436996
references: Biol Psychiatry. 2001 Dec 1;50(11):884-97
references: 11743943
references: East Asian Arch Psychiatry. 2012 Mar;22(1):7-11
references: 22447799
references: Int Clin Psychopharmacol. 2001 Nov;16(6):325-30
references: 11712620
references: Am J Psychiatry. 2004 Feb;161(2 Suppl):1-56
references: 15000267
references: Soc Psychiatry Psychiatr Epidemiol. 2004 May;39(5):337-49
references: 15133589
references: Curr Med Res Opin. 2010 Oct;26(10):2403-10
references: 20812791
references: Br J Psychiatry. 2001 Feb;178:154-8
references: 11157428
references: Acta Psychiatr Scand Suppl. 2003;(416):7-15
references: 12755849
references: World J Biol Psychiatry. 2005;6(3):132-91
references: 16173147
references: Br J Psychiatry. 1992 Dec;161:783-90
references: 1483164
references: J Clin Psychiatry. 2005 Sep;66(9):1122-9
references: 16187769
references: World J Biol Psychiatry. 2006;7(1):5-40
references: 16509050
references: Psychiatry Res. 2011 Feb 28;185(3):456-8
references: 20554016
references: Schizophr Bull. 2004;30(2):295-302
references: 15279047
references: Schizophr Res. 2008 Feb;99(1-3):192-9
references: 17851042
references: Br J Psychiatry. 2000 Jul;177:20-5
references: 10945083
references: Pharmacoepidemiol Drug Saf. 2012 Feb;21(2):161-9
references: 21858898
references: Rev Saude Publica. 2011 Feb;45(1):14-23
references: 21085885
references: Acta Psychiatr Scand. 2005 Jul;112(1):54-63
references: 15952946
references: Am J Psychiatry. 2004 Apr;161(4):692-9
references: 15056516
references: Psychiatr Serv. 2004 Aug;55(8):928-30
references: 15292543
references: Eur Neuropsychopharmacol. 2007 Mar;17(4):235-44
references: 17137759
references: Aust N Z J Psychiatry. 2003 Aug;37(4):452-7
references: 12873330
references: BMC Psychiatry. 2010 Jan 28;10:11
references: 20109170
references: Psychopharmacology (Berl). 2011 Aug;216(4):475-84
references: 21369751
references: J Clin Psychiatry. 2004 Mar;65(3):312-21
references: 15096069
references: Br J Psychiatry. 2004 Apr;184:346-51
references: 15056580
references: Schizophr Res. 1997 Dec 19;28(2-3):199-206
references: 9468354
references: BMC Psychiatry. 2010 Jan 07;10:2
references: 20059765
references: Value Health. 2009 Jun;12(4):536-43
references: 19900255
references: Prog Neuropsychopharmacol Biol Psychiatry. 2004 May;28(3):487-95
references: 15093956
references: Psychiatr Serv. 2011 Oct;62(10):1138-45
references: 21969639
references: Schizophr Bull. 2010 Jan;36(1):71-93
references: 19955390
references: J Clin Psychiatry. 2004 Jun;65(6):864-6
references: 15291666
references: Int J Equity Health. 2012 Jan 20;11:2
references: 22264309
references: Soc Psychiatry Psychiatr Epidemiol. 2011 Nov;46(11):1095-101
references: 20972771
references: Schizophr Bull. 2008 Nov;34(6):1163-71
references: 18156640
references: Psychol Med Monogr Suppl. 1992;20:1-97
references: 1565705
references: J Clin Psychiatry. 2011 Dec;72(12):1616-27
references: 22244023
references: Pharmacopsychiatry. 2012 Jul;45(5):177-81
references: 22290206